ADS Biosystems Inc.

ADS Biosystems Inc. has a very experienced and highly skilled team and provides a wide range of services for academia and industry customers. We have a number of repeat customers, such as Celgene, Genentech, Sanofi Europe, UCSD, Intercept, and Third Rock Ventures, just to name a few. Our featured services include, but not limited to, antigen-based affinity antibody purification, in vitro kinase assays, Alpha Screen, and custom ELISA kit formation and testing . We specialize in cell-based assays, such as human M1 macrophage Caspase 1 activation, and many other luciferase-based assays in cells, such as FXR based luciferase assays in cells. Our expertise is on human CD34+ hematopoietic stem cells and differentiation into human T cells. We specialize in cell-based assays, such as luciferase assays, in a variety of primary cells, cell lines and tissue cultures. We also provide molecular biology services such as real time RT-PCR, quantitative Western Blot and ELISA, and human cell mutation tests; cell biology services such as stable cell lines with designated reporters, cell differentiation studies with brown and white adipocytes, human adult stem cells, and cochlear organ culture for hearing studies; in vivo mouse model studies for obesity and diabetes. We are capable of testing drug candidates for hearing loss studies in our chemically deafened cochlear cultures, and for obesity and diabetes in vitro with adipocytes and in vivo with mouse models. Sample shipment instructions: Tissues and cells on dry ice Services: - Custom genomic deletion and mutation tests of human cells and cell lines - Gene expression profiling and real-time RT PCR (Taqman assays) of human tissues and cell lines -Protein expression with quantitative Western blot analyses and ELISA - Primary cell culture and cochlear organ culture - Custom stable cell lines from human and murine adult stem cells - Custom testing for brown and white fat differentiation in primary human cultures - Custom lentiviral-mediated human stable cell lines with different reporters such as luciferases - Custom shRNA gene knockdown in human and mouse stable cell lines - In vivo custom studies of the effects of high fat diet on commercial and/or custom genetic mouse models for obesity and diabetes and in vivo rodent glucose and insulin tolerance tests Assay development**: - Custom biochemical and cell-based assay development; routine human and mouse cell-based assays with custom reporters and endogenous gene expression such as Northern blot analyses, real time RT PCR and protein level detection with quantitative Western blot assays and ELISA; quantitative assays for variations in endogenous signal transduction pathways; specialty assay development for human brown and white adipocyte differentiation in obesity and diabetes, and cochlear organ culture in hearing loss and restoration. **We are happy to buy commercially available animal models, obesity/diabetes models, cochlea hearing mouse model, tumor models, breast cancer models. We also have access to the following cell lines: cancer cell lines, lung, breast, other routine cell lines like leukemia and lymphoma, fibroblast, mostly human. Our main focus is primary cells, and we can create genetically modified models, mouse fibroblast, etc. Preclinical drug discovery and development: - Custom testing of drug candidates for efficacy in human and mouse cell lines, human adult stem cells and cochlear cultures with designated reporters, endogenous gene expression and effects on endogenous signal transduction pathways; in vivo testing of drug candidates in rodents. Instrumentation: - Li-cor Odyssey: detects fluorescence, quantifies the signal, very sensitive up to several magnitudes, used to quantify individual bands to compare to loading control References: - Wang Z, Shah OJ, Hunter T (2012). The transcriptional coactivators p/CIP and SRC-1 control insulin resistance through IRS1 in obesity models. PLoS One.2012;7(7):e36961. Epub 2012 Jul 31. - Wang Z, Qi C, Krones A, Woodring P, Zhu X, Reddy JK, Evans RM, Rosenfeld MG, and Hunter T. (2006). In vivo roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance. Cell Metabolism 3:111-122. - Shah OJ, Wang Z, Hunter T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current Biology 14:1650 - Lu Z, Ghosh S, Wang Z, Hunter T. (2003). Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 4:499 - Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG. (2000). Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A. 97:13549 Patents: - Thies S, Farouz F, Wang Z, Jacques B, and Lu J. Small molecule compounds to treat hearing loss. International publication number: WO2013/126805A2 - Wong L, Xu S, Ding J. Biomarker Assays for detecting or measuring inhibition of TOR kinase activity. Patent application number: 20120028972 - Wisniewski M, Kwong W, Mohsenian F, Ding J. Nucleic acid preparation composition and methods. International publication number: WO 2010/115016 A2